<DOC>
	<DOCNO>NCT00665626</DOCNO>
	<brief_summary>The purpose study determine whether Spleen Tyrosine Kinase ( Syk ) Inhibitor , R935788 ( R788 ) dose 100 mg , tablet , orally , twice-a-day effective treatment Rheumatoid Arthritis patient 'failed ' biologic therapy .</brief_summary>
	<brief_title>Efficacy Safety Study R935788 Tablets Treat Rheumatoid Arthritis ( Taski-3 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients must give write informed consent sign IRB/ECapproved Informed Consent Form ( ICF ) prior admission study . Males female , 18 year age old , active RA least 12 month prior Day 1 dose Are currently receive previously receive biologic therapy inhibitor TNF , rituximab , abatacept , anakinra approve label dose â‰¥3 month prior Day 1 dose designate biologic therapy failure lack efficacy , safety , tolerability . Patients may receive stable dos methotrexate ( MTX ) , azathioprine ( combination MTX ) , leflunomide ( combination MTX ) , sulfasalazine , chloroquine , hydroxychloroquine , gold , NSAIDs ( include COX2 inhibitor ) , minocycline , doxycycline . The dose must stable least 30 day prior Day 1 dosing must change washout , screen treatment period , unless dictate tolerability requirement . Patients take MTX must receive weekly MTX dos ( 7.525 mg/week ) minimum 3 month prior Day 1 dose must receive stable MTX dose , change route , previous 6 week prior Day 1 dosing . Patients receive MTX must also receive folic folinic acid supplementation stable dose least 6 week prior Day 1 dosing . Females childbearing potential must fully inform potential R788 adversely affect fetus , sexually active , must agree use well establish method birth control study ( oral contraceptive , mechanical barrier , long act hormonal agent ) . These patient must lactate must negative urine pregnancy test time randomization laboratory determination . The patient must otherwise good health determine Investigator basis medical history , physical examination , laboratory screening test screen period . See exclusion criterion specific exclusion . In Investigator 's opinion , patient ability understand nature study hazard participation , communicate satisfactorily Investigator participate , comply , requirement entire protocol . The patient history , concurrent , clinically significant illness , medical condition ( arthritis ) laboratory abnormality , Investigator 's opinion , could affect conduct study . Specifically , exclude patient follow : 1. uncontrolled poorly control hypertension ; 2. autoimmune disease ( psoriatic arthritis , lupus , mixed connective disorder ) arthritis syndrome ( gout , Lyme disease , Reiter 's syndrome ) ; 3. recent serious surgery infectious disease ; 4. recent history ( , treatment , malignancy nonmelanomatous skin cancer , history lymphoma ; 5 . Hepatitis B ; 6 . Hepatitis C ; 7. interstitial pneumonitis active pulmonary infection chest xray 8 . Tuberculosis ( TB ) 9. know laboratory abnormalities The patient history substance abuse , drug addiction alcoholism . Patients may consume 4 unit alcohol per week ; however , alcohol avoid 72 hour prior lab assessment . Patients reliably comply exclude . A unit alcohol define follow : Beer=12 oz 355 mL ; wine = 5 oz 148 mL ; sweet dessert wine=3 oz 89 mL ; 80 proof distil spirits= 1.5 oz 44 mL . The patient treat previously treat R788 different protocol . The patient pacemaker , aneurysm clip contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>